CLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read MoreCLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read MoreSCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read MoreFinancial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read MoreKommuniqué I
Liebe Freunde, Aktionäre, Wir sind in ein neues Jahr eingetreten, eines voller...
Read MoreCLINUVEL Communiqué I
Dear friends, shareholders, We have entered a new year, one brimmed with...
Read MoreCLINUVEL Newsletter VI
Dear shareholders, friends, CLINUVEL’S OUTLOOK The past weeks have seen a flurry...
Read MoreSCIENTIFIC COMMUNIQUÉ VIII
DNA Repair Mechanisms December 2020 Introduction DNA is the repository of genetic...
Read MoreSCIENTIFIC COMMUNIQUÉ VII
The Cerebral Vasculature System in Disease: Atherosclerosis Introduction The human brain is...
Read MoreChair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read MoreSCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read MoreKommuniqué V, 20-23 September 2020
Liebe Aktionäre, Freunde, Während die Welt darum kämpft, die Verbreitung von...
Read MoreCLINUVEL Newsletter V
Dear shareholders, friends, As the world battles on to control the...
Read MoreCLINUVEL Newsletter
Dear shareholders, friends, As a new world presents itself indicating that the...
Read More